NCT00112658 2021-03-08
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
UNICANCER
Phase 2/3 Completed
Clinical Trials
10 trialsNCT03098030 2020-12-09
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
United Therapeutics
Phase 2/3 Completed
NCT02172976 2020-09-02
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma
Krankenhaus Nordwest
Phase 2/3 Completed
NCT00952029 2020-03-30
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2/3 Completed
NCT01550055 2019-04-10
CRC009
Shanghai Zhangjiang Biotechnology Limited Company
Phase 2/3 Completed
NCT01523431 2017-03-30
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2/3 Completed
NCT00975897 2013-12-19
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT00284258 2012-11-02
Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer
Taiho Pharmaceutical Co., Ltd.
Phase 2/3 Completed
NCT00639327 2011-06-28
Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer
Japan Clinical Cancer Research Organization
Phase 2/3 Completed
NCT00192712 2010-11-10
Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
Rambam Health Care Campus
Phase 2/3 Completed